Hepatitis C: the 'silent stalker'.
D000998:Antiviral Agents / Q000627:therapeutic use; D004797:Enzyme-Linked Immunosorbent Assay; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy* / Q000821:virology; D018937:Hepatitis C Antibodies; D006801:Humans; D015151:Immunoblotting; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D009154:Mutation; D011092:Polyethylene Glycols; D016133:Polymerase Chain Reaction; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use; D012307:Risk Factors; D014481:United States / Q000453:epidemiology
D000998:Antiviral Agents; D018937:Hepatitis C Antibodies; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a